Autoantibodies as risk factors for threatened miscarriage in women with early pregnancy loss


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The association between obstetric complications and antiphospholipid antibodies (aPLs) and autoantibodies directed against hormones and complement components has attracted considerable scientific and practical interest. Aim. To investigate the diagnostic value of autoantibodies and risk factors for threatened miscarriage in women with early pregnancy loss. Materials and methods. Eighty women with early pregnancy losses, including pregnant women with (subgroup 1, n=29) and without (subgroup 2, n=20) threatened miscarriage were tested for antibodies to cardiolipin (CL), ß2-glycoprotein-1 (ß2-GP-I), phosphatidylserine/prothrombin complex (PS/PT), phosphatidylethanolamine (PE), component C1q, human chorionic gonadotropin (hCG), and progesterone (Pg) using ELISA. Results. Antibodies directed against hormones were found in 40-45% of patients, 23.8%-33.8% had antibodies to ß2-GP-I, CL, PE, PS, and 11.3% to PS/PT. IgA-antibodies to ß2-GP-Iand CL were detected in 16.3% and 6.3% of patients, respectively. Levels of aPL, antibodies to hormones, and C1q were higher in subgroup 1 than in subgroup 2. High odds ratios (>10) were observed for antibodies to ß2-GP-I, PE, and Pg. Conclusion. Determination of antibodies to ß2-GP-I, CL, hormones, and C1q has a high diagnostic value for identifying early threatened miscarriage, and antibodies to ß2- GP-I, PE, and PG are possible risk factors.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Irina Menzhinskaya

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Dr. Med. Sci., Leading Researcher at the Laboratory of Clinical Immunology Moscow, Russia

Teya Ionanidze

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Junior Researcher at the 2nd Obstetric Department of Pathology of Pregnancy Moscow, Russia

Ludmila Van’ko

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Dr. Med. Sci., Professor, Leading Researcher at the Laboratory of Clinical Immunology Moscow, Russia

Nana Tetruashvili

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Dr. Med. Sci., Head of the 2nd Obstetric Department of Pathology of Pregnancy Moscow, Russia

Lubov Krechetova

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Dr. Med. Sci., Head of the Laboratory of Clinical Immunology Moscow, Russia

Әдебиет тізімі

  1. DIppolito S., Ticconi C., Tersigni C., Garofalo S., Martino C., Lanzone A. et al. The? pathogenic role of autoantibodies in recurrent pregnancy loss. Am. J. Reprod. Immunol. 2020; 83(1): e13200. https://dx.doi.org/10.1111/aji.13200.
  2. Kwak-Kim J., Agcaoili M.S., Aleta L., Liao A., Ota K., Dambaeva S. et al. Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome. Am. J. Reprod. Immunol. 2013; 69(6): 596-607. https://dx.doi.org/10.1111/aji.12114.
  3. DIppolito S., Meroni P.L., Koike T., Veglia M., Scambia G., Di Simone N. Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun. Rev. 2014; 13(9): 901-8. https://dx.doi.org/10.1016/j.autrev.2014.05.004.
  4. Cervera R. Antiphospholipid syndrome. Thromb. Res. 2017; 151(Suppl. 1): S43-7. https:/l/dx.doi.org/10.1016/S0049-3848(17)30066-X.
  5. Bertolaccini M.L., Amengual O., Atsumi T., Binder W.L., de Laat B., Forastiero R. et al. ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International congress on antiphospholipid antibodies, Galveston, TX, USA, April 2010. Lupus. 2011; 20(2): 191-205. https://dx.doi.org/10.1177/0961203310397082.
  6. Rodriguez- Garcia V., Ioannou Y., Fernandez-Nebro A., Isenberg D.A., Giles I.P. Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology 2015; 54(11): 2042-50. https://dx.doi.org/10.1093/rheuhmlatology/kev226.
  7. Meijide H., Sciascia S., Sanna G., Khamashta M.A., Bertolaccini M.L. The clinical relevance of IgA anticardiolipin and IgA anti-ß2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun. Rev. 2013; 12(3): 421-5. https://dx.doi.org/10.1016/j.autrev.2012.08.002.
  8. Conti F., Alessandri C., Sorice M., Capozzi A., Longo A., Garofalo T. et al. Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome. Clin. Exp. Immunol. 2012; 167(3): 429-37. https://dx.doi.org/10.1111/j.1365-2249.2011.04532.x.
  9. Sugi T. Kininogen-dependent antiphosphatidylethanolamine antibodies and autoantibodies to factor XII in patients with recurrent pregnancy loss. J. Obstet. Gynaecol. Res. 2013; 39(7): 1223-9. https://dx.doi.org/10.1111/jog.12110.
  10. Amengual O., Forastiero R., Sugiura-Ogasawara M., Otomo K., Oku K., Favas C. et al. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus. 2017; 26(3): 266-76. https://dx.doi.org/10.1177/0961203316660203.
  11. Kouser L., Madhukaran S.P., Shastri A., Saraon A., Ferluga J., Al-Mozaini M., Kishore U. Emerging and novel functions of complement protein C1q. Front. Immunol. 2015; 6: Article 317. https://dx.doi.org/10.3389/fimmu.2015.00317.
  12. Ohmura K., Oku K., Kitaori T., Amengual O., Hisada R., Kanda M. et al. Pathogenic roles of anti-C1q antibodies in recurrent pregnancy loss. Clin. Immunol. 2019; 203: 37-44. https://dx.doi.org/10.1016/j.clim.2019.04.005.
  13. Менжинская И.В., Ванько Л.В. Ассоциация антител к гонадотропинам и женским половым гормонам с нарушениями репродуктивной функции. Акушерство и гинекология. 2017; 9: 20-7. https://dx.doi.org/10.18565/aig.2017.9.20-7
  14. Менжинская И.В., Гладкова К.А., Сидельникова В.М., Сухих Г.Т. Антипрогестероновые антитела в клинике привычной потери беременности. Иммунология. 2008; 1: 34-7
  15. Менжинская И.В., Кашенцева М.М., Ванько Л.В., Сухих Г.Т. Иммунохимические свойства аутоантител к хорионическому гонадотропину у женщин с невынашиванием беременности. Иммунология. 2015; 36(1): 30-5
  16. Pericleous C., Ferreira I., Borghi O., Pregnolato F., McDonnell T., Garza-Garcia A. et al. Measuring IgA anti-beta2-glycoprotein I and IgG/ IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One. 2016; 11: e0156407. https://dx.doi.org/10.1371/journal.pone.0156407.
  17. Cabrera-Marante O., Rodriguez de Frias E., Serrano M., Lozano Morillo F., Naranjo L., Gil-Etayo FJ. et al. The Weight of IgA anti-ß2glycoprotein I in the antiphospholipid syndrome pathogenesis: closing the gap of seronegative antiphospholipid syndrome. Int. J. Mol. Sci. 2020; 21(23): 8972. https://dx.doi.org/10.3390/ijms21238972.
  18. Yonezawa M., Kuwabara Y., Ono S., Ouchi N., Ichikawa T., Takeshita T. Significance of anti-phosphatidylethanolamine antibodies in the pathogenesis of recurrent pregnancy loss. Reprod. Sci. 2020; 27(10): 1888-93. https://dx.doi.org/10.1007/s43032-020-00208-4.
  19. Zigon P., Podovsovnik A., Ambrozic A., Tomsic M., Hocevar A., Gaspersic N. et al. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements. Clin. Rheumatol. 2019; 38(2): 371-8. https://dx.doi.org/10.1007/s10067-018-4251-7.
  20. Mekinian A., Bourrienne M.C., Carbillon L., Benbara A., Noemie A., Chollet-Martin S. et al. Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: Prevalence and treatment efficacy in pregnancies. Semin. Arthritis Rheum. 2016; 46(2): 232-7. https://dx.doi.org/10.1016/j.semarthrit.2016.05.006.
  21. Kitaori T., Sugiura-Ogasawara M., Oku K., Papisch W., Ebara T., Ozaki Y. et al. Determination of clinically significant tests for antiphospholipid antibodies and cutoff levels for obstetric antiphospholipid syndrome. Lupus. 2015; 24(14): 1505-19. https://dx.doi.org/10.1177/0961203315595128.
  22. Корнюшина Е.А., Чепанов С.В., Сельков С.А., Дадаева Д.Г., Шахалиев Р.А., Чудотворов К.Н., Немсцверидзе Н.Н. Профилактика потери беременности у женщин с циркуляцией аутоантител, не входящих в критерии антифосфолипидного синдрома. Журнал акушерства и женских болезней. 2018; 67(6): 24-30
  23. Oku K., Amengual O., Hisada R., Ohmura K., Nakagawa I., Watanabe T. et al. Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome. Rheumatology (Oxford). 2016; 55(8): 1403-11. https://dx.doi.org/10.1093/rheumatology/kew196.
  24. Defendi F., Thielens N.M., Clavarino G., Cesbron J.Y., Dumestre-Perard C. The immunopathology of complement proteins and innate immunity in autoimmune disease. Clin. Rev. Allergy Immunol. 2020; 58(2): 229-51. https://dx.doi.org/10.1007/s12016-019-08774-5.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>